Xeris at H.C. Wainwright conference: growth engine widens

Xeris reaffirmed at least 33% revenue growth for the current year, following 40%-50% growth in the prior year, supported by approximately 85% and improving gross margins. The company expects RECORLEV to reach $1 billion in revenue by 2030 and projects $750 million of total company revenue by 2030. Xeris introduced XP-8121, a once-weekly subcutaneous hypothyroidism therapy targeting a 3 million-5 million patient population and a potential $1 billion-$3 billion market, with development to be internally funded. The pipeline opportunity remains contingent on successful non-inferiority trial results, regulatory approval and payer reimbursement, while XERS shares have fallen 12.66% over the past week despite gaining 36.45% over six months.

Analysis

The investable issue is whether XERS can convert a high-margin, single-franchise growth profile into durable operating leverage before pipeline spend rises. The current valuation should be anchored to RECORLEV execution, not XP-8121: Cushing’s is a concentrated prescriber market where incremental field-force and hub-service costs can outrun revenue if new-patient starts normalize. The recent drawdown creates an entry only if upcoming quarterly prescription growth and gross-to-net trends confirm that commercial expansion is producing productive revenue rather than simply higher access costs.

XP-8121 is economically more binary than management frames it. Non-inferiority in controlled patients may be sufficient for approval, but payer adoption will depend on demonstrable persistence of control, reduced monitoring/titration burden, and a tightly operationalized prior-authorization pathway; a generic comparator makes net pricing and access the principal commercial risk. The 40% screening-failure observation is hypothesis-generating rather than proof of a reimbursable population, and the 48-54 week endpoint structure pushes a meaningful clinical de-risking catalyst well beyond the next 12 months.

The contrarian case is that the market may eventually assign little value to XP-8121 even after approval unless real-world evidence identifies a reproducible, high-cost uncontrolled subgroup. Conversely, if XERS documents reduced physician workload and fewer repeat labs in gastrointestinal-malabsorption or polypharmacy cohorts, payers could view the product as a medical-cost-offset therapy rather than a premium convenience formulation—supporting materially better penetration than a standard specialty launch.

Near term, watch for revenue growth deceleration, selling-and-marketing growth versus net sales, cash burn after R&D acceleration, and any revision to RECORLEV’s long-range trajectory. A sustained miss in new patient starts or deterioration in gross margin would undermine the self-funding narrative and raise dilution risk before XP-8121’s value can be realized.

Key Decisions for Investors

• Initiate only a starter long in XERS over the next 1-3 months, scaled after the next earnings release confirms RECORLEV-led growth remains above 30% while operating cash flow covers incremental R&D. Treat XP-8121 as free optionality rather than underwriting value; target 2:1 upside/downside with a stop or thesis review on a material guidance cut.
• Add to XERS on evidence that commercial spend is becoming more efficient: quarterly net-product revenue growth exceeding sales-and-marketing expense growth, stable-to-improving gross margin, and no increase in external-financing needs. These metrics matter more than conference commentary.
• Do not buy long-dated XP-8121 catalyst exposure yet. Establish a clinical watch item around trial enrollment, protocol/regulatory updates, and Touchstone evidence defining a payer-verifiable failure population; absent these data, approval probability and post-approval net pricing cannot be modeled credibly.
• For a diversified healthcare book, fund any XERS position by trimming a mature, slower-growth specialty-pharma exposure rather than pairing against large-cap pharma. XERS-specific execution—not broad drug-pricing policy—is the dominant driver over the next 6-18 months.